Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29846180 | 1.00 | KCNA3 (0.49) | KCNA3MAOBMAOAPPARGF2RL3 | |
| SCHEMBL31359541 | 0.79 | MAOB (0.47) | KCNA3MAOBMAOAPIN1 | |
| SCHEMBL28434999 | 0.78 | ABCB1 (0.47) | MAOBPPARGF2RL3PIN1ABCB1 | |
| SCHEMBL31359519 | 0.78 | HPGD (0.55) | KCNA3MAOBMAOA | |
| SCHEMBL31359542 | 0.77 | MAOB (0.48) | KCNA3MAOBMAOA | |
| SCHEMBL31359523 | 0.77 | MAOB (0.45) | KCNA3MAOBMAOAPIN1 | |
| SCHEMBL31359539 | 0.77 | MAOB (0.48) | KCNA3MAOBMAOA | |
| SCHEMBL27489226 | 0.77 | MAOB (0.53) | MAOBF2RL3ABCB1HTR1ADRD2 | |
| SCHEMBL3372411 | 0.76 | MAOB (0.64) | KCNA3MAOBMAOAHTR1ADRD2 | |
| SCHEMBL28108815 | 0.76 | MAOB (0.59) | MAOBPPARGABCB1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112074521-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-112074521-A | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2020-12-11 | — | — | CN | disclosed |